AlphaTON Capital Executes Option to Divest Biotech Subsidiary iOx, Potentially Unlocking Over $100M in Milestones

summarizeSummary

AlphaTON Capital has signed a binding call option agreement to sell its iOx Therapeutics subsidiary, a legacy biotech asset, to Immunova, LLC, with potential milestone payments exceeding $100 million, equity, and royalties.

check_boxKey Events

• Binding Call Option Agreement Signed

  AlphaTON Capital executed a binding call option agreement to grant Immunova, LLC the option to acquire its wholly-owned subsidiary, iOx Therapeutics Limited.

• Significant Potential Financial Upside

  Upon exercise, AlphaTON is entitled to an upfront cash payment, 10% fully diluted equity in the acquiring entity, milestone payments potentially exceeding $100 million, and single-digit royalties on future net sales.

• Strategic Portfolio Streamlining

  The divestiture of iOx Therapeutics, a legacy biotech asset, allows AlphaTON to unlock value and focus on its Telegram super-app and new AI-driven biotech initiatives.

• Contingent on Financing

  The call option's exercise is subject to certain conditions, including Immunova securing financing commitments, introducing an element of uncertainty.

auto_awesomeAnalysis

This transaction represents a significant strategic move for AlphaTON Capital, allowing it to divest a legacy biotech asset and potentially secure substantial non-dilutive capital through milestone payments, equity, and royalties. Given the company's recent initiation of a massive $400 million At-The-Market (ATM) offering, this deal could provide a crucial alternative funding source and reduce reliance on dilutive capital raises. The divestiture also aligns with the company's stated pivot towards its Telegram super-app and new AI-driven biotech initiatives, streamlining its portfolio and focusing resources on its core strategic areas. Investors should monitor the progress of Immunova's financing commitments and the eventual exercise of the call option, as the successful completion of this transaction could materially impact AlphaTON's financial position and strategic direction.